Table 1.
Baseline characteristics of the study subjects
| All | Recurrence | Non-recurrence | p-value | |
|---|---|---|---|---|
| Patients, n | 69 | 11 | 58 | – |
| Age, years | 43.7 ± 13.4 | 43.4 ± 13.5 | 43.8 ± 13.5 | 0.923 |
| Sex (male/female) | 40/29 | 10/1 | 28/30 | 0.019 |
| Dialysis/Preemptive kidney transplantation | 53/16 | 9/2 | 44/14 | 1.000 |
| Living related donor | 36 (52.2) | 7 (63.6) | 29 (50.0) | 0.406 |
| Panel reactive activity > 50% | 10 (14.5) | 0 (0) | 10 (17.2) | 0.345 |
| Desensitization treatment | 13 (18.8) | 1 (9.1) | 12 (20.7) | 0.676 |
| Number of HLA mismatches | 2.88 ± 1.84 | 2.45 ± 1.97 | 2.97 ± 1.82 | 0.354 |
| ABO incompatible transplantation | 10 (14.5) | 1 (9.1) | 9 (15.5) | 1.000 |
| Induction treatment (ATG/anti-IL-2) | 0/68 | 0/10 | 0/58 | 0.159 |
| Mean follow up duration after transplantation (days) | 1835 ± 440 | 1782 ± 542 | 1845 ± 423 | 0.663 |
| Time to transplantation from dialysis (days, IQR) | 1387 ± 1611 (84–2109) |
1514 ± 1477 (219–2516) |
1360 ± 1652 (83–2133) |
0.568 |
| Acute rejection | 32 (46.4) | 8 (72.7) | 24 (41.4) | 0.056 |
| Mean time of recurrence of IgA on allograft (days, IQR) | – | 614 ± 443 (390–726) |
– | – |
| Serum creatinine (at time of recurrence, mg/dL) | 2.96 ± 1.52 | |||
| eGFR-time slope (delta eGFR/year) | −3.64 ± 4.88 | −4.50 ± 3.99 | −3.47 ± 5.04 | 0.302 |
| HLA-A2 | 30 (43.5) | 6 (54.5) | 24 (41.4) | 0.514 |
| HLA-B35 | 12 (17.4) | 2 (18.2) | 10 (17.2) | 1.000 |
| HLA-DR4 | 40 (58.0) | 9 (81.8) | 31 (53.4) | 0.104 |
| Tacrolimus | 66 (95.7) | 10 (90.9) | 56 (96.6) | 0.411 |
| Cyclosporine | 7 (10.1) | 2 (18.2) | 5 (8.6) | 0.309 |
| Mycophenolate mofetil | 53 (76.8) | 7 (63.6) | 46 (79.3) | 0.265 |
| Trough level of tacrolimus within one year from transplantation | 8.30 ± 1.70 | 8.92 ± 1.38 | 8.19 ± 1.74 | 0.218 |
| TNFSF13 (ng/mL) | 16.03 ± 12.95 | 17.75 ± 14.14 | 15.66 ± 12.79 | 0.525 |
| Gd-IgA1 (units/ng IgA) | 5.77 ± 6.79 | 3.28 ± 1.43 | 6.35 ± 7.40 | 0.208 |
HLA human leucocyte antigen, ATG anti-thymocyte globulin, IL-2 interleukin-2, IQR interquartile range, eGFR estimated glomerular filtration rate, TNFSF13 Tumor necrosis factor superfamily 13, Gd-IgA1 Galactose deficient-IgA1